GlobeNewswire: argenx SE Contains the last 10 of 295 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T01:29:06ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/27/2852890/0/en/argenx-Advances-Clinical-Development-of-Efgartigimod-in-Primary-Sjogren-s-Disease.html?f=22&fvtc=4&fvtv=30298argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease 2024-03-27T06:00:00Z<![CDATA[]]>https://www.globenewswire.com/news-release/2024/03/26/2852715/0/en/argenx-Announces-Annual-General-Meeting-of-Shareholders-on-May-7-2024.html?f=22&fvtc=4&fvtv=30298argenx Announces Annual General Meeting of Shareholders on May 7, 20242024-03-26T20:00:00Z<![CDATA[March 26, 2024]]>https://www.globenewswire.com/news-release/2024/03/26/2852095/0/en/argenx-Announces-Approval-of-VYVGART-efgartigimod-alfa-in-Japan-for-Adults-with-Primary-Immune-Thrombocytopenia.html?f=22&fvtc=4&fvtv=30298argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia2024-03-26T06:00:00Z<![CDATA[VYVGART® now approved in Japan for both generalized myasthenia gravis and primary immune thrombocytopenia (ITP)]]>https://www.globenewswire.com/news-release/2024/03/07/2842711/0/en/argenx-Delivers-on-Promise-to-Transform-Patient-Expectations-in-Autoimmunity-at-American-Academy-of-Neurology-2024-Annual-Meeting.html?f=22&fvtc=4&fvtv=30298argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting2024-03-07T21:01:00Z<![CDATA[ADHERE data presentation will highlight first potential innovation for CIDP patients in 30 years]]>https://www.globenewswire.com/news-release/2024/02/29/2837584/0/en/argenx-Reports-Full-Year-2023-Financial-Results-and-Provides-Fourth-Quarter-Business-Update.html?f=22&fvtc=4&fvtv=30298argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update2024-02-29T06:00:00Z<![CDATA[$374 million in fourth quarter and $1.2 billion in full year global net product sales]]>https://www.globenewswire.com/news-release/2024/02/26/2834787/0/en/argenx-to-Present-at-Upcoming-Investor-Conferences.html?f=22&fvtc=4&fvtv=30298argenx to Present at Upcoming Investor Conferences2024-02-26T06:00:00Z<![CDATA[February 26, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following investor conferences in March:]]>https://www.globenewswire.com/news-release/2024/02/22/2833283/0/en/argenx-to-Report-Full-Year-2023-Financial-Results-and-Fourth-Quarter-Business-Update-on-February-29-2024.html?f=22&fvtc=4&fvtv=30298argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 20242024-02-22T06:00:00Z<![CDATA[February 22, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, February 29, 2024 at 2:30 PM CET (8:30 AM ET) to discuss its full year 2023 financial results and provide a fourth quarter business update.]]>https://www.globenewswire.com/news-release/2024/02/20/2831497/0/en/argenx-Announces-FDA-Acceptance-of-Supplemental-Biologics-License-Application-with-Priority-Review-for-VYVGART-Hytrulo-in-Chronic-Inflammatory-Demyelinating-Polyneuropathy.html?f=22&fvtc=4&fvtv=30298argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy 2024-02-20T06:00:00Z<![CDATA[Prescription Drug User Fee Act (PDUFA) target action date is June 21, 2024]]>https://www.globenewswire.com/news-release/2024/01/18/2811228/0/en/argenx-Announces-Approval-of-VYVDURA-efgartigimod-alfa-and-hyaluronidase-qvfc-Injection-for-Subcutaneous-Use-in-Japan-for-Generalized-Myasthenia-Gravis.html?f=22&fvtc=4&fvtv=30298argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis 2024-01-18T06:00:00Z<![CDATA[Jan. 18, 2024, 7:00 AM CET]]>https://www.globenewswire.com/news-release/2024/01/08/2805041/0/en/argenx-Highlights-2024-Strategic-Priorities.html?f=22&fvtc=4&fvtv=30298argenx Highlights 2024 Strategic Priorities 2024-01-08T06:00:00Z<![CDATA[Reported $1.2 billion in preliminary* full-year 2023 global net product sales]]>